- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04540796
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
March 26, 2024 updated by: Janssen Research & Development, LLC
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-75348780 in participants with relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to further characterize the safety at the RP2D(s) in Part B.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
B-cell lymphoid malignancies include CLL and NHL and are defined by clonal populations of B-lymphocytes expressing identical surface antigens.
CD22 is a surface protein specifically expressed on B-lymphocytes and is expressed in B-lymphocytic malignancies.
It is known to negatively regulate the B-cell receptor via its cytosolic immunoreceptor tyrosine-based inhibitory motifs.
JNJ-75348780 is a novel human bispecific antibody that recognizes the CD3 antigen on T-lymphocytes and the CD22 antigen on mature and malignant B-lymphocytes.
JNJ-75348780 is hypothesized to lead to cytotoxicity, T-cell activation, and induction of cytokines upon engagement of CD3 on T-cells and CD22 on malignant B-lymphocytes.
The study consists of screening phase, treatment phase and post-treatment phase.
The total study duration will be up to 2 years 10 months.
Efficacy assessments will include radiographic image assessments, positron emission tomography scan, bone marrow assessment, endoscopy or colonoscopy, physical examinations.
Safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
147
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
-
Heidelberg, Australia, 3084
- Austin Hospital
-
Nedlands, Australia, 6009
- Linear Clinical Research Ltd
-
-
-
-
-
Lille, France, 59037
- CHRU de Lille - Hopital Claude Huriez
-
NANTES Cedex 1, France, 44093
- CHU Nantes
-
Pierre Benite, France, 69495
- Centre Hospitalier Lyon-Sud
-
-
-
-
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Haifa, Israel, 34362
- Carmel Medical Center
-
Jerusalem, Israel, 9112001
- Hadassah Medical Center
-
Ramat Gan, Israel, 74047
- Sheba Medical Center
-
Tel Aviv, Israel, 6423906
- Tel Aviv Sourasky MC
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 06591
- The Catholic University of Korea Seoul St. Mary'S Hospital
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital de Vall D'Hebron
-
Barcelona, Spain, 8916
- Hosp. Univ. Germans Trias I Pujol
-
Madrid, Spain, 28040
- Hosp. Univ. Fund. Jimenez Diaz
-
Pamplona, Spain, 31008
- Clinica Univ. de Navarra
-
Salamanca, Spain, 37007
- Hosp. Clinico Univ. de Salamanca
-
-
-
-
-
Kaohsiung, Taiwan, 83301
- Chang-Gung Memorial Hospital, Kaohsiung
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
Taichung, Taiwan, 40402
- China Medical University Hospital
-
Tainan, Taiwan, 70403
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10048
- National Taiwan University Hospital
-
-
-
-
-
Leicester, United Kingdom, LE1 5WW
- Leicester Royal Infirmary
-
London, United Kingdom, SE5 9RS
- King's College Hospital
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust
-
Plymouth, United Kingdom, PL6 8DH
- Plymouth Hospital NHS Trust
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologic documentation of disease: B-cell NHL or CLL requiring therapy; All participants must have relapsed or refractory disease with no other approved therapies available that would be more appropriate in the investigator's judgment. B cell NHL as defined per the 2016 World Health Organization (WHO) classification: In addition, the following disease-specific criteria outlined below must be met a) If diffuse large B-cell lymphoma (DLBCL): received, or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent, b) If follicular lymphoma (FL)/ marginal zone lymphoma (MZL) (except mucosa-associated lymphoid tissue [MALT]), or Waldenstrom macroglobulinemia (WM): previously treated with a minimum of 2 prior lines of systemic therapy, with at least 1 prior line containing an anti-CD20 antibody, c) If mantle cell lymphoma (MCL): previously treated with at least 1 prior line of systemic therapy containing an anti-CD20 antibody. CLL or small lymphocytic lymphoma (SLL): relapsed or refractory with at least 2 prior lines of therapy to include a bruton tyrosine kinase inhibitor (BTKi) and/or a B-cell lymphoma (BCL)2 inhibitor, if eligible. For Part B: participants must have measurable disease as defined by the appropriate disease response criteria
- Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1
- Cardiac parameters within the following range: corrected QT interval (QTc intervals corrected using Fridericia's formula [QTcF]) less than or equal to (<=) 480 milliseconds (ms) based on the average of triplicate assessments performed no more than 5 (plus minus [+ -] 3) minutes apart
- Women of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta human chorionic gonadotropin) at screening and prior to the first dose of study drug
- Women must be: a) not of childbearing potential, b) of childbearing potential and practicing a highly effective, preferably user independent method of contraception (failure rate of less than (<) 1 percent (%) per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study drug and until 90 days after last dose
Exclusion Criteria:
- Known central nervous system (CNS) involvement with lymphoma
- Prior solid-organ transplantation
- Either of the following: a) received an autologous stem cell transplant <=3 months before the first dose of JNJ 75348780, b) prior treatment with allogenic stem cell transplant <= 6 months before the first dose of JNJ-75348780, or has evidence of graft versus host disease that requires immunosuppressant therapy
- Prior chemotherapy, targeted therapy, immunotherapy or radiotherapy (with the exclusion of palliative radiation to limited sites that do not interfere with response assessment based on a sufficient number of other sites), within 2 weeks before the first administration of study drug. For investigational agents where the half-life is known, there should be a treatment-free window of at least 2 weeks or 5 half-lives, whichever is longer. For investigational agents with long half-lives a wash-out of 4 weeks is acceptable. Participants who received prior treatment with anti-CD20 * anti-CD3 bispecific therapy will be excluded until a dedicated cohort(s) is opened as determined by the SET
- Active autoimmune disease that requires systemic immunosuppressive medications (example, chronic corticosteroid, methotrexate, or tacrolimus)
- History of malignancy (other than the disease under study in the cohort to which the participant is assigned) within 1 year prior to the first administration of study drug. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy which in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 1 year before the first dose of study drug. Concomitant malignancies that are unlikely to progress and/or preclude evaluation of study endpoints may be allowed after discussion with the Study Responsible Physician
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part B: Cohort Expansion
Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.
|
Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
|
Experimental: Part A: Dose Escalation
Participants will receive JNJ-75348780.
The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along with the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.
|
Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A and Part B: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Time Frame: Up to 2 years 10 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
|
Up to 2 years 10 months
|
Part A and Part B: Number of Participants with AEs by Severity
Time Frame: Up to 2 years 10 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death).
Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
|
Up to 2 years 10 months
|
Part A and Part B: Number of Participants with Dose-Limiting Toxicity (DLT)
Time Frame: Up to 28 days
|
Number of participants with DLT will be assessed.
The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Concentration-time Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-75348780
Time Frame: Up to 2 years 10 months
|
AUCtau is the measure of the serum drug concentration from time zero to end of dosing interval.
|
Up to 2 years 10 months
|
Maximum Observed Serum Concentration (Cmax) of JNJ-75348780
Time Frame: Predose, 48 hours postdose (up to 2 years 10 months)
|
Cmax is the maximum observed serum concentration of JNJ-75348780.
|
Predose, 48 hours postdose (up to 2 years 10 months)
|
Minimum Observed Serum Concentration (Cmin) of JNJ-75348780
Time Frame: Predose, 48 hours postdose (up to 2 years 10 months)
|
Cmin is the minimum observed serum concentration of JNJ-75348780.
|
Predose, 48 hours postdose (up to 2 years 10 months)
|
Objective Response Rate (ORR)
Time Frame: Up to 2 years 10 months
|
ORR is defined as the percentage of participants who achieve a partial response (PR) or better according to the revised response criteria for malignant lymphoma, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) response criteria and International Workshop for Waldenstrom Macroglobulinemia (IWWM) response criteria.
|
Up to 2 years 10 months
|
Complete Response (CR) Rate
Time Frame: Up to 2 years 10 months
|
CR rate is defined as the percentage of participants who achieve a best response of CR according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.
|
Up to 2 years 10 months
|
Time to Response (TTR)
Time Frame: Up to 2 years 10 months
|
TTR is defined for participants who achieved PR or CR as the time from the first dose of study drug to first response of PR or CR according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.
|
Up to 2 years 10 months
|
Duration of Response (DOR)
Time Frame: Up to 2 years 10 months
|
DOR is defined for participants who achieved PR or CR as the time between the date of initial documentation of PR or CR to the date of either the first documented evidence of disease progression or death according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.
|
Up to 2 years 10 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2020
Primary Completion (Estimated)
April 4, 2025
Study Completion (Estimated)
May 9, 2025
Study Registration Dates
First Submitted
September 2, 2020
First Submitted That Met QC Criteria
September 2, 2020
First Posted (Actual)
September 7, 2020
Study Record Updates
Last Update Posted (Actual)
March 27, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Hematologic Diseases
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Leukemia
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
Other Study ID Numbers
- CR108882
- 2020-001183-29 (EudraCT Number)
- 75348780LYM1001 (Other Identifier: Janssen Research & Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinicaltrials/
transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
Clinical Trials on JNJ-75348780
-
Janssen Research & Development, LLCRecruitingLymphoma, Non-HodgkinDenmark, Israel, Spain, Australia
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Johnson & Johnson Enterprise Innovation Inc.RecruitingAdvanced Solid TumorsUnited States
-
Janssen Cilag N.V./S.A.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Research & Development, LLCActive, not recruitingLymphoma, Non-Hodgkin | Chronic Lymphocytic LeukemiaUnited States, Israel, Korea, Republic of, Netherlands, Belgium, Spain, Australia, Poland, France, Georgia, Moldova, Republic of, Ukraine